Research Analysts Set Expectations for SXTP Q1 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Investment analysts at Ascendiant Capital Markets issued their Q1 2027 EPS estimates for 60 Degrees Pharmaceuticals in a research note issued on Wednesday, May 20th. Ascendiant Capital Markets analyst L. Ward forecasts that the company will post earnings per share of ($0.90) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $3.70 price target on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($3.16) per share. Ascendiant Capital Markets also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2027 earnings at ($0.88) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.89) EPS.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.44 million.

Several other research firms also recently weighed in on SXTP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 27th. HC Wainwright downgraded shares of 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 20th. Finally, Wall Street Zen downgraded shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 12th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.85.

60 Degrees Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ SXTP opened at $1.50 on Wednesday. 60 Degrees Pharmaceuticals has a twelve month low of $1.29 and a twelve month high of $14.68. The company has a market capitalization of $3.99 million, a PE ratio of -0.17 and a beta of 2.69. The firm has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $2.78.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.